CRISPR Therapeutics AG Stock News

Cathie Wood is known for seizing opportunities. The founder of Ark Invest doesn't worry when one of the stocks she's invested in drops, and instead, she looks at the movement as a chance to increase her bet -- at a great price.

ZUG, Switzerland and BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that a late-breaking oral presentation highlighting the Company's Phase 1 clinical data of its investigational CRISPR/Cas9 in vivo gene editing therapy, CTX310™, targeting ang...

Last week, the SPDR S&P Biotech ETF surged 6%.

CRISPR Therapeutics AG (NASDAQ:CRSP ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 8:30 AM EDT Company Participants Samarth Kulkarni - CEO & Chairman Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Good morning, everybody.

CRISPR Therapeutics AG (NASDAQ:CRSP ) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 4:30 PM EDT Company Participants Raju Prasad - Chief Financial Officer Conference Call Participants Mitchell Kapoor - H.C.

CRISPR stock is a bold investment in the future. Beyond the valuation, thematically and based on current market dynamics, I consider this a venture-style winner. Just because CRISPR stock may be a winning lottery ticket, that doesn't mean you negate grand strategy. Getting lucky may get you rich, but strategy establishes you as wealthy. Risks demand a portfolio that's at least resilient and at ...

ZUG, Switzerland and BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in September.

Small biopharma story stocks just aren't paying off like they used to. Maybe there are just too many of them, with each one working on a medical breakthrough that's statistically unlikely to even come close to an approval.